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Abstract
A high percentage of oesophageal adenocarcinomas show an aggressive clinical behaviour with a significant resistance to
chemotherapy. Heat-shock proteins (HSPs) and glucose-regulated proteins (GRPs) are molecular chaperones that play an
important role in tumour biology. Recently, novel therapeutic approaches targeting HSP90/GRP94 have been introduced for
treating cancer. We performed a comprehensive investigation of HSP and GRP expression including HSP27, phosphorylated
(p)-HSP27(Ser15), p-HSP27(Ser78), p-HSP27(Ser82), HSP60, HSP70, HSP90, GRP78 and GRP94 in 92 primary resected oesophageal
adenocarcinomas by using reverse phase protein arrays (RPPA), immunohistochemistry (IHC) and real-time quantitative RT-
PCR (qPCR). Results were correlated with pathologic features and survival. HSP/GRP protein and mRNA expression was
detected in all tumours at various levels. Unsupervised hierarchical clustering showed two distinct groups of tumours with
specific protein expression patterns: The hallmark of the first group was a high expression of p-HSP27(Ser15, Ser78, Ser82) and
low expression of GRP78, GRP94 and HSP60. The second group showed the inverse pattern with low p-HSP27 and high
GRP78, GRP94 and HSP60 expression. The clinical outcome for patients from the first group was significantly improved
compared to patients from the second group, both in univariate analysis (p = 0.015) and multivariate analysis (p = 0.029).
Interestingly, these two groups could not be distinguished by immunohistochemistry or qPCR analysis. In summary, two
distinct and prognostic relevant HSP/GRP protein expression patterns in adenocarcinomas of the oesophagus were
detected by RPPA. Our approach may be helpful for identifying candidates for specific HSP/GRP-targeted therapies.
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Introduction
Oesophageal adenocarcinoma arising from precancerous Bar-
rett’s Metaplasia (Barrett’s Carcinoma) is a very aggressive tumour
and is often diagnosed only at an advanced stage. Despite
advances in surgery and the introduction of neoadjuvant treatment
of locally advanced carcinomas, the prognosis for invasive
oesophageal adenocarcinoma is poor, with a five-year survival
rate of less than 50% [1,2]. This may also be due to the
considerable rate of chemotherapy resistance in these tumours [3–
6]. For that reason, it is of major importance to develop
individualised therapeutic concepts and alternative therapeutic
strategies beyond conventional chemotherapeutic or surgical
treatment to improve the current treatment of patients with this
disease.
Although there is increasing knowledge about the molecular
background of this disease [7], to date, no valid biomarkers have
been identified to predict prognosis or chemotherapy response.
Previously, we showed that the regulation and expression of
several molecular chaperones such as heat-shock proteins (HSPs)
and glucose-regulated proteins (GRPs) may have an important
impact on the tumour biology of oesophageal adenocarcinomas
with respect to prognosis and chemotherapy response [8,9].
Moreover, novel therapeutic approaches targeting HSPs and
GRPs have been studied in preclinical models and in part
introduced for cancer treatment [10–14]. However most data
about HSP and GRP expression have been generated from
smaller sample collections and/or focussed on selected proteins.
Given the complexity of regulation of molecular chaperones it is
likely that the biological behaviour of tumours may be influenced
by the interaction and crosstalk between these molecules rather
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than by alterations of one single protein. In view of the presumed
prognostic significance of HSPs and GRPs, we now performed a
comprehensive expression analysis of the heat-shock proteins
HSP60, HSP70, HSP90 and HSP27 (including its phosphorylated
forms p-HSP27(Ser15), p-HSP27(Ser78), p-HSP27(Ser82)) and the
glucose-regulated proteins GRP 94 and GRP78 in a well-
characterized collection of primary resected oesophageal adeno-
carcinomas from patients who received neither neo-adjuvant nor
adjuvant treatments. We analysed the expression of these proteins
using reverse phase protein array (RPPA) technology, which also
allows quantitative analysis of protein expression from formalin-
fixed, paraffin-embedded (FFPE) tissue [15,16]. Additionally,
immunohistochemistry and real-time quantitative RT-PCR
(qPCR) were carried out. The results of the expression studies
were correlated with pathological features and patients’ clinical
outcome.
Materials and Methods
Ethics Statement
All patients gave informed written consent, and the study was
approved by the Ethics Committee of the Technische Universita¨t
Mu¨nchen, Munich, Germany (#2056/08).
Patient Characteristics and Tissue Samples
Formalin-fixed, paraffin-embedded (FFPE) tumour samples
from 92 patients with oesophageal adenocarcinomas, who were
treated between 1991 and 2006 in the department of surgery of
the Klinikum Rechts der Isar der Technischen Universita¨t
Mu¨nchen, Germany, were investigated. Primary resection of the
tumours was conducted by trans-thoracic or trans-hiatal oesoph-
agectomy without (neo-)adjuvant chemotherapy or radioche-
motherapy. The resection specimens were processed immediately
after surgery i.e. they were opened by a pathologist and fixed in
4.5% buffered formalin for 24–48 hours. Patient and tumour
characteristics are given in Table 1. The median age of the
patients was 62 (range 33–82). Of the 92 patients included in this
study, 51 patients died of disease, with a median overall survival
(OS) of 33.2 months (95% CI= 17.9–48.5) and a median disease-
free survival (DFS) of 31 months (95% CI= 22.7–39.3).
Protein Extraction and Antibodies
Protein extraction was performed as previously described [16].
Briefly, FFPE tumour tissue from three 10 mm sections was
deparaffinized (xylene for two times 10 min) and rehydrated
(100%/90%/70% ethanol for five min each). The tumour tissue
was microdissected, and approximately 0.5 cm2 tissue from three
10 mm-thick sections was processed in 100 ml of extraction buffer
(EXB Plus, Qiagen GmbH, Hilden, Germany). Haemorrhagic or
necrotic areas were excluded to obtain a percentage of tumour
tissue of at least 80%. Protein concentrations were determined
using the Bradford protein assay according to the manufacturer’s
instructions (BioRad, Hercules, CA). Randomly selected lysates
were probed for b-actin by Western blot to verify the success of the
protein extraction and the suitability of the material for RPPA
analysis. All protein lysates that were analysed showed a clear b-
actin band by Western blot. Before performing RPPA for HSP/
GRP expression analysis, all antibodies were validated by Western
blot using proteins extracted from formalin-fixed tissues. A
detailed list of the antibodies used is given in Table 2.
Reverse Phase Protein Arrays (RPPA)
RPPAs were generated using the Calligrapher MiniArrayer
(BioRad, Hercules, CA) in accordance with the manufacturer’s
instructions [17,18]. For every lysate and every dilution (undiluted,
1:2, 1:4, 1:8, 1:16, buffer), three replicates were applied to a
nitrocellulose-coated glass slide (Grace Bio-Labs, Bend, OR) to
obtain a total of 18 data points per sample. Peroxidase blocking
was performed in accordance with the manufacturer’s instructions
(Dako, Glostrup, Denmark). Immunodetection was performed
similar to a Western blot, as previously described [19]. For the
estimation of the total protein amount, arrays were stained in
parallel with Sypro Ruby Protein Blot Stain (Molecular Probes,
Eugene, OR) in accordance with the manufacturer’s instructions.
Quantitative Protein Analysis
The TIFF images for the antibody-stained slides and Sypro
Ruby-stained slides were analysed with MicroVigene 3.5.0.0
software (VigeneTech, Carlisle, MA). The MicroVigene signal-
intensity points (MVS) were calculated by the integral of a logistic
four-point fit model, which was matched optimally to the 18 data
points that were obtained.
Immunohistochemistry
Immunohistochemical staining was performed using tissue
microarrays, which were constructed for the purpose of this study
and contained samples from all 92 tumours. Antigen retrieval was
performed in accordance with the manufacturer’s recommenda-
tions. After deparaffination and rehydration, heat-induced antigen
Table 1. Clinico-pathologic characteristics of the patients.
Factor Number of patients %
92
Gender
Male 78 84.8
female 15 16.3
UICC pT catergory
pT1 30 32.6
pT2 21 22.8
pT3 41 44.6
UICC pN category
pN0 46 50
pN1/2 46 50
Metastases
cM0 84 91.3
cM1 8 8.7
Tumour grading
G1 2 2.2
G2 39 42.4
G3 51 55.4
Resection status
R0 76 82.6
R1 16 17.4
Survival
alive 41 44.6
dead of disease 51 55.4
pT: tumour status as determined in pathology; pN: lymph node status as
determined in pathology; cM: occurrence of distant metastases as determined
by attending physician, cM0: no distant metastases, cM1: distant metastases
present.
doi:10.1371/journal.pone.0041420.t001
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retrieval was performed using 10 mM citrate buffer, pH 6.
Subsequent to H2O2 blocking using 3% H2O2 in aqua dest. and
Avidin Biotin blocking (Avidin/Biotin blocking kit; Vector
Laboratories, Inc., Burlingame, CA, USA), the sections were
incubated with antibodies for HSPs, followed by a secondary
biotinylated antibody. Immunodetection was performed using the
Dako REALTM Detection system Peroxidase/DAB + kit (DAKO,
Glostrup, DK). A detailed list of the antibodies and the dilutions is
presented in Table 2.
The evaluation of immunohistochemical staining was per-
formed at least by three independent observers (KB, JSH, ED).
Differences were discussed at a double-header microscope to gain
a final consensus. The expression was assessed based on the
intensity of cytoplasmatic immunostaining and the percentage of
stained tumour cells. The intensity was scored as 0 (negative), 1
(weak staining), 2 (moderate staining) or 3 (strong staining). The
percentage of positive tumour cells was scored as 0 (none), 1
(,10%), 2 (10–50%), 3 (51–80%) or 4 (.80%). Multiplication of
the scores for intensity and percentage resulted in a semiquanti-
tative immunoreactive score ranging from 0 to 12. Examples of
immunohistochemical staining are shown in the File S1. For
GRP94 and GRP78, the staining results from a previously
published study were used [20].
Real-Time Quantitative RT-PCR (qPCR)
Microdissection, RNA extraction and cDNA synthesis were
performed as described previously with minor modifications [21].
After tissue preparation, as described above, the microdissected
tumour tissue was transferred into a sterile 1.5-ml tube containing
RNA lysis buffer. Lysis was carried out at 60uC for 24 hours until
the tissue was completely solubilised. RNA was purified by phenol
and chloroform extraction followed by precipitation with an equal
volume of isopropanol in the presence of 20 ml of 2 mol/L sodium
acetate (pH 4.0) and 2 ml of 10 mg/ml glycogen at 220uC. The
RNA pellet was washed once in 70% ethanol, dried and
resuspended in 20 ml of RNase-free water. One microgram of
RNA was transcribed into cDNA using Superscript II reverse
transcriptase (Invitrogen) and 250 ng of random hexamers (Roche
Diagnostics, Penzberg, Germany) in accordance with the manu-
facturer’s recommendations, in a final volume of 20 ml. Gene
expression was quantified using RealTime ready single assays
(Roche Diagnostics) for the target genes GRP94 (ID 100489),
HSP27 (ID 100497), HSP70 (ID 110730), GRP78 (ID 110805),
HSP90 (ID 138013) and HSP60 (ID 137175), and the housekeep-
ing genes PPIA (ID 102088), ALAS1 (ID 102108) and ACTB (ID
101125). Housekeeping genes were selected in a previous study
using the RealTime ready Reference Gene Panel (Roche
Diagnostics), which contains 19 different reference genes to
facilitate the identification of the most suitable genes from eight
different carcinoma samples. Using the GeNorm software, the
reference genes PPIA, ALAS1 and ACTB were shown to be most
stably expressed in all tissues analysed. qPCR was performed in
triplicate with the LightCycler 480 Instrument using LightCycler
480 Probes Master (Roche Diagnostics) and 10 ng of cDNA per
well. Thermal cycler conditions comprised 45 cycles at 95uC for
10 s, 60uC for 30 s, and 72uC for 1 s. Relative mRNA expression
was calculated by the DDCt method using the LightCycler 480
Software with an efficiency-corrected algorithm with standard
curves and triple normalization to PPIA, ALAS1 and ACTB as
reference genes.
Statistical Analysis
Unsupervised hierarchical clustering was performed using
Cluster and TreeView software. Following log transformation
and centre to median calculations, average hierarchical clustering
was performed using the Spearman rank correlation [22]. SPSS
statistical software (IBM SPSS statistics 19) was used for additional
statistical analysis. Associations between groups of patients were
given in cross tabs and differences were determined using the x2-
test. Comparisons between groups were performed using non-
parametric tests (Mann-Whitney U test; Kruskal Wallis test,
Spearman rank correlation). Survival was calculated from the day
of surgery. Patients with incomplete tumour resection (R1), the
presence of distant metastases (cM1) at the time of surgery, or
death within the first 30 days after surgery were excluded from the
survival analysis that was performed using Kaplan-Meier esti-
mates, log-rank tests and Cox’s proportional hazards regression
analysis. All tests were two-sided, and the significance level was set
at five %.
Results
Quantitative Protein Expression of HSPs and GRPs by
RPPA
RPPA analysis could be carried out for 87 tumour samples; for
five cases, there was not enough material for RPPA. Represen-
tative RPPA results for the unphosphorylated and the phosphor-
ylated forms of HSP27 are given in Figure 1. Median quantitative
Table 2. Antibodies used for immunohistochemistry (IHC) and for Western blot (WB)/RPPA analysis.
IHC WB/RPPA
Protein Antibody Distributor Dilution
HSP27 #2402 Cell signalling, Danvers, USA 1:250 1:1000
Phospho-HSP(Ser15) #ab39399 Abcam, Cambridge, UK 1:500 1:1000
Phospho-HSP(Ser78) #2405 Cell signalling, Danvers, USA 1:500 1:1000
Phospho-HSP(Ser82) #2401 Cell signalling, Danvers, USA 1:100 1:1000
HSP60 #ab46798 Abcam, Cambridge, UK 1:2000 1:2000
HSP70 #ab17850 Abcam, Cambridge, UK 1:1 1:50
HSP90 #ab1429 Abcam, Cambridge, UK 1:100 1:200
GRP78 #ab32618 Abcam, Cambridge, UK 1:1000 1:1000
GRP94 #sc1794 Santa Cruz Biotechnology Inc., CA, USA 1:5000 1:500
doi:10.1371/journal.pone.0041420.t002
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protein expression (protein/SyproRuby*1000) was as follows:
HSP27:725 (range 0–6127), p-HSP27(Ser15):788 (range 185–
3246), p-HSP27(Ser78): 850 (range 215–3671), p-HSP27(Ser82):
793 (range 0–4307), HSP60:866 (range 112–3232), HSP70:744
(range 151–5292), HSP90:796 (range 206–3130), GRP94:818
range (0–4222) and GRP78:857 (range 174–3240). We first
analysed the expression levels of single proteins, and found no
correlation between any of the HSPs or GRPs and pathologic
parameters (UICC pTNM classification, tumour differentiation)
(File S2). Moreover, survival analysis for the single markers
revealed no significant association of any protein with overall or
disease-free survival, except for a trend in association between very
high p-HSP27(Ser15) levels (4th quartile) and better overall and
disease-free survival (p = 0.073 and p= 0.11, respectively).
We next performed unsupervised hierarchical clustering to
generate a tumour-specific protein expression pattern (Figure 2A).
Two clusters (Clusters A and B) of the 87 patients analysed could
be distinguished by their protein expression patterns: Cluster A
(n= 34) consisted of carcinomas that showed a high abundance of
HSP 27 and its phosphorylated forms (abbreviated p-HSP27) and
low expression of GRP78, GRP94, HSP60, HSP70 and HSP90.
Cluster B (n = 53) consisted of carcinomas with the inverse
expression pattern (low (p-)HSP 27 and high GRP78, GRP94,
HSP60, HSP70 and HSP90 expression) (Figure 2B).
To further assess the relevance of the specific HSP and GRP
protein expression patterns identified, we compared the patholog-
ical features and the clinical outcome of the different patient
groups. Patients from Cluster B were more likely to have lymph
node metastases, although this difference was not statistically
Figure 1. Illustration of Reverse Phase Protein Arrays (RPPA). As an example to illustrate the concept of RPPA, the results of four arrays
probed with antibodies against HSP27 and its phosphorylated forms (Ser78, Ser82, Ser15) are shown. Tumour samples on the arrays which were not
included in the study are marked with an ‘‘x’’. Additionally, Western blots for these four antibodies are shown, to demonstrate their reliability. These
images are shown for clarification; the signals must not be compared directly, as they are not normalised to the total protein content of the sample.
doi:10.1371/journal.pone.0041420.g001
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significant (p = 0.073). For the other factors (pT category, distant
metastases, and tumour differentiation), no correlation was found.
According to the criteria given above, survival analysis was
conducted for 82 patients. Interestingly, the survival analysis
showed a better prognosis for patients from Cluster A (n= 32)
compared to patients from Cluster B (n= 50), with a prolonged
overall survival (median OS 87 months; 95% CI= 59–114 months
vs. 28 months; 95% CI= 16–40 months; p = 0.015; Figure 3A)
and a significantly prolonged disease-free survival (median DFS
87 months; 95% CI= 30–143 months vs. 25 months; 95%
CI= 9–40 months; p = 0.010; Figure 3B). Other factors that
showed significant prognostic value in univariate analysis were:
UICC pT category (OS: p,0.001; DFS: p = 0.001), presence/
absence of lymph node metastases (SO and DFS: p,0.001),
Figure 2. Hierarchical cluster analysis of oesophageal adenocarcinomas according to the protein expression of HSP and GRP
measured by RPPA. Unsupervised hierarchical cluster analysis of 87 oesophageal adenocarcinomas based on the expression of HSP27, HSP60,
HSP70, HSP90, the phosphorylated forms of HSP27 (Ser78, Ser82, Ser15), GRP 78 and GRP94, as analysed by RPPA, identified two clusters (Clusters A
and B) with specific protein profiles (A). The hallmark of Cluster A is high expression of the phosphorylated HSP27 (p-HSP27) and the low expression
of HSP78, GRP94 and HSP60. The hallmark of Cluster B is the inverse of Cluster A. Cluster colour key: Red – up-regulated; green – down-regulated;
black – unchanged; grey – missing. Boxplots (B) illustrating the different protein expression levels assessed by RPPA analysis in tumours from Clusters
A and B, as identified by hierarchical cluster analysis.
doi:10.1371/journal.pone.0041420.g002
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presence/absence of distant metastases (OS and DFS: p= 0.001),
complete/incomplete tumour resection (OS: p= 0.001; DFS:
p = 0.002). Multivariate analysis including UICC pT and pN
category, tumour grading, and the clustered protein expression
pattern showed that protein expression was the best independent
prognostic indicator for overall (p = 0.029) and disease-free
survival (p = 0.012) besides lymph node status (p = 0.004 and
p= 0.010, respectively) (Tables 3 and 4).
Immunohistochemistry
Immunohistochemical staining intensities of tumours ranged
from negative (score 0) to very high (score 12) for HSP90 and from
negative to high (score 8) for HSP27, p-HSP27(Ser15), HSP60 and
HSP70. For p-HSP27(Ser78) and p-HSP27(Ser82), negative vs.
positive staining was assessed on the basis of single cells. Low
HSP60 IHC reactivity was observed in early tumours (pT1;
p = 0.009) and also in tumours without lymph node metastases
(p = 0.003). For the other markers, there were no associations
between pathologic parameters and IHC reactivity (see File S3).
There was no association between IHC staining patterns and
patient outcome.
Expression Analysis of HSP and GRP mRNA
Real-time quantitative RT-PCR analysis was performed for all
92 tumours. mRNA from the target genes was detectable at
various levels in cancer tissues from all patients analysed. The
relative median mRNA expression levels (ratio of target gene/
housekeeping genes *1000) were HSP27:60 (range 10–220),
HSP60:2530 (650–11430), HSP70:1210 (300–4510), HSP90:790
(220–5110), GRP78:491 (90–1660) and GRP94:1080 (440–3780).
A significantly elevated level of HSP27 mRNA expression was
found in advanced tumour stages (pT2/3) as compared to early
stages (pT1; p = 0.009). mRNA levels of HSP60, HSP70, HSP90,
GRP78 and GRP94 did not correlate with pathological features
(pT, pN, grade), as summarized in File S4. In the survival
analysis, high HSP27 mRNA levels were associated with better
overall survival (p = 0.022) in univariate analysis. For the other
markers, no significant association between gene expression and
prognosis was evident.
Correlation between RPPA Analysis, qPCR and
Immunohistochemistry
In general, there was no strong correlation between HSP/GRP
mRNA and protein expression levels, as measured either by RPPA
analysis or by immunohistochemistry (File S5). However, for
HSP90 and HSP60, a significant correlation was found between
mRNA expression levels and the immunohistochemical staining
intensity (p = 0.003, p = 0.02). For HSP27, a correlation was found
Figure 3. Survival analysis for oesophageal adenocarcinoma patients. Kaplan-Meier survival curves for 82 patients from Clusters A and B
with respect to overall survival (A) and disease-free survival (B). Patients who died within the first month after surgery (N = 5) were excluded from the
survival analysis.
doi:10.1371/journal.pone.0041420.g003
Table 3. Multivariate Cox regression analysis (Overall
survival).
Factor Exp 95% CI for Exp(B) p-value
min max
pTcategory 1.079 0.65 1.789 0.769
lymph node status 3.569 1.507 8.454 0.004
distant metastases 2.148 0.828 5.569 0.116
tumour grading 1.354 0.742 2.471 0.323
Resection status 1.542 0.652 3.648 0.324
Cluster A vs. B 2.247 1.087 4.645 0.029
Statistically significant p-values are marked in bold letters. pT-category: pT1 vs.
pT2 vs. pT3; lymph node status:absent vs. present; distant metastases: absent
vs. present; tumour grading: G1 vs. G2 vs. G3; resection status: R0 vs. R1/2.
doi:10.1371/journal.pone.0041420.t003
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between mRNA expression and protein expression level as
measured by RPPA analysis (p = 0.01). However, no direct
correlation was found between protein expression levels detected
by RPPA analysis and immunohistochemical staining results.
Thus, the two patient groups identified by quantitative protein
expression clustering (Clusters A and B) could not be distinguished
by either qPCR or immunohistochemistry.
Discussion
Heat-shock proteins (HSPs) and glucose-regulated proteins
(GRPs) are highly conserved molecular chaperones, which are
responsible for maintaining cellular integrity by promoting the
correct folding of newly translated or denatured proteins. HSPs
and GRPs are also referred to as stress proteins, because their
expression can be up-regulated by pathological conditions such as
acidosis, hypoxia or hyper- or hypothermia. HSPs and GRPs also
play an important role in the regulation of apoptosis [23,24]. In
recent years, knowledge about the association of HSPs and GRPs
with cancer and their important role in cancer biology has
increased. Molecular chaperones have been suggested to influence
tumour growth, differentiation and resistance to radio- and
chemotherapy treatment, and may have a major impact on the
final clinical outcome of patients with cancer [25–29]. For
example, overexpression of HSP27 was associated with a poor
clinical outcome in patients with rectal cancer [30]. Externaliza-
tion of HSP70 onto the cell membrane has been shown to be
tumour-specific in colon cancer cells and appears to correlate with
patient prognosis [31]. In oesophageal squamous cell cancer
patients, HSP70 autoantibodies were significantly increased in
patients’ sera so that HSP70 has been suggested as a diagnostic
marker [14]. Other studies have addressed the prognostic
significance of GRP 96 and HSP90 in oesophageal squamous cell
carcinomas [32–34].
Our group previously reported that in oesophageal adenocar-
cinomas, the expression of GRP78 and GRP94 varies depending
on the tumour stage, with high expression levels mostly occurring
either in very early or advanced stages, suggesting the complex
regulation of GRPs in response to different kinds of stresses [20].
In another study, proteomic analysis followed by IHC and
validation of gene expression level showed an association between
high HSP27 expression and response to neoadjuvant chemother-
apy in a collection of multimodal treated cases [8]. Most recently,
we demonstrated that tumours with low expression of phosphor-
ylated HSP27-family proteins and high expression of HER-family
proteins were characterized by an aggressive biological behaviour
[9]. These previous works focussed on selected heat shock proteins.
However, the complex regulation with interactions between the
various members of the HSP/GRP family are well documented
[35,36]. Therefore, identification of expression patterns of several
molecules may be superior over the analysis of single markers. In
order to comprehensively elucidate the role and the regulation of
HSPs and GRPs in oesophageal adenocarcinomas, we studied the
expression of HSP27, phosphorylated (p)-HSP27(Ser15), p-
HSP27(Ser78), p-HSP27(Ser82), HSP60, HSP70, HSP90, GRP78
and GRP94 in a well-characterized, homogenously treated
collection of patients with primary resected oesophageal adeno-
carcinomas. We incorporated some data for HSP27 and p-HSP27,
that have already been published by our group in the context of a
clustering analysis with proteins from signal transduction pathways
[9], but have not been presented as raw data and in combination
with other HSPs and with GRPs, which is provided in the present
paper. Here we show that a protein expression pattern of low p-
HSP27(Ser15, Ser78, Ser82) and high GRP78/GRP94/HSP60 in the
tumours was significantly associated with a poorer prognosis and
that this particular protein expression profile was superior to
conventional pathologic prognostic factors of the UICC TNM
classification system in multivariate analysis. In particular, patients
who showed a high abundance of phosphorylated HSP27 protein
together with low expression levels of GRP78, GRP94 and HSP60
(Cluster A) had better survival rates as compared to patients with
the inverse expression pattern (Cluster B). This indicates that
HSP/GRP protein expression and regulation might play a
significant role in the tumour biology of oesophageal adenocar-
cinomas, as has already been shown in other cancer types
[27,36,37]. Moreover, the association of a higher abundance of
phosphorylated HSP27 protein with superior survival is in
accordance with the observation that HSP27 phosphorylation
leads to the downregulation of its chaperone activity and impairs
resistance to oxidative stress [38]. The association of high
expression levels of GRP78, GRP94 and HSP60 in tumours with
a more aggressive clinical behaviour might lead to new therapy
strategies, as therapeutic agents that inhibit HSPs and GRPs have
been developed in recent years and have already been shown to
act as powerful anti-tumour agents both alone and in combination
with conventional chemo- or radiochemotherapy [10–12,14,39–
41].
We have identified the prognostic, highly significant, distinct
HSP/GRP-expression patterns in oesophageal adenocarcinomas
by unsupervised hierarchical cluster analysis from the results of
quantitative protein expression analysis using reverse phase
protein array (RPPA) technology. This method has emerged as a
powerful tool for the molecular characterization of cellular
material. Using RPPA, it is possible to perform quantitative
protein expression analysis of single proteins, to study posttran-
scriptional modifications such as phosphorylation or to generate
signalling networks of groups of proteins. Application of RPPA for
the identification of dysregulated pathways in tumour cells and for
the investigation of drug response in human malignancies such as
breast cancer [42,43], lung carcinomas [44], prostate cancer [45]
or non-solid neoplasms like leukemias [46] has been previously
published. For the investigation of large case collections with well
characterized patient data the most widely used material in cancer
research represent the formalin-fixed, paraffin-embedded (FFPE)
tissue collections which are stored in the pathology departments.
Due to marked technical improvements the usage of this tissue
now has become possible for a large range of different molecular
methods. Therefore, not only robust molecular analyses like
immunohistochemistry or DNA based investigations, but also
Table 4. Multivariate Cox regression analysis (Disease free
survival).
Factor Exp(B) 95% CI for Exp(B) p-value
min max
pTcategory 1.227 0.759 1.982 0.404
lymph node status 2.89 1.286 6.493 0.01
distant metastases 2.551 0.976 6.668 0.056
tumour grading 1.252 0.698 2.246 0.451
Resection status 1.227 0.531 2.836 0.633
Cluster A vs. B 2.477 1.219 5.034 0.012
Statistically significant p-values are marked in bold letters. pT-category: pT1 vs.
pT2 vs. pT3; lymph node status:absent vs. present; distant metastases: absent
vs. present; tumour grading: G1 vs. G2 vs. G3; resection status: R0 vs. R1/2.
doi:10.1371/journal.pone.0041420.t004
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more sensitive methods like microRNA or mRNA can be applied
as a reliable approach in the search for biomarkers [47]. As
described recently by our group [48–50], the highly promising
RPPA technology is also suitable for the investigation of samples
from FFPE tissue. However, pre-analytic parameter like time point
and duration of fixation, ischemia time etc. may heavily influence
the results of tissue based analyses. Assuring and reporting quality
of biospecimen which are used for research has become an
important matter of debate [51,52]. According to the standard
operation procedures in our department [53], the processing of
oesophageal carcinoma specimens is standardized with only
minimal time intervals between resection and formalin fixation.
Therefore we consider our sample collection as highly homoge-
nous in this regard. Moreover, we investigated untreated, primary
resected tumours to exclude any influence on gene or protein
expression which may be caused by cytotoxic preoperative
treatment.
The most striking result from our study was that the prognostic
protein expression pattern could only be detected by RPPA and
did not correlate with mRNA gene expression analysis or
immunohistochemistry (with the exception of a concordant trend
for HSP27). However, some correlation was found between
immunoreactivity and mRNA expression for HSP60 and HSP90.
While it is well known that proteomic and genomic information
often fail to correlate due to different kinetics of post-translational
modifications or protein turnover [54], the predominant lack of
correlation between immunohistochemistry and RPPA detected
here was unexpected. This absence of correlation may be due to
the higher sensitivity of RPPA as compared to the semiquantitative
immunohistochemical staining. Moreover, expression levels as
measured by RPPA include protein expression in stroma cells,
which are present even in microdissected tumour samples. RPPA
technology may deliver more subtle and accurate proteomic
information as compared to immunohistochemistry and therefore
may serve as an additional tool to characterize protein profiles of
neoplastic and non-neoplastic cells and tissues. A possible bias
concerning the interpretation of immunohistochemical analysis of
molecular markers, however, could be marked intratumoral
heterogeneity. This may limit the usage of tissue microarray
technology in this context. We have addressed this problem in a
recently published work, where we could not demonstrate a
significant difference between full slide sections and TMA cores for
the estimation of the expression levels of heat-shock proteins in
gastrointestinal carcinomas [55]. We therefore conclude that
intratumoral heterogeneity may not be the cause for the lack of
correlation between PPPA and IHC. Furthermore we were not
able to exactly reproduce the results of a preceding study about
GRP78 and GRP94 gen-expression in the present work. This
reason for this may be the application of a different methodical
approach of RNA analysis reflecting the development of technical
advances in this field. Moreover, when analysing single protein
expression levels in our study, it was not possible to detect a
relevant correlation between the clinical behaviour of the tumours
in contrast to the combined expression patterns of p-HSP27(Ser15,
Ser78, Ser82)/GRP78/GRP94/HSP60. Thus, these findings dem-
onstrate the superiority of the identification of expression patterns
of several molecular markers over the analysis of single molecules.
In summary, we detected two distinct, biologically relevant
expression patterns of HSPs/GRPs in oesophageal adenocarcino-
mas by RPPA which was the best ‘‘biomarker’’ for prognosis
besides lymph node status. The identification of this specific
protein expression pattern in patients with a more aggressive
clinical behaviour not only enhances the understanding regarding
the pathogenesis of this cancer, but it might also lead the way to
new specific therapy strategies directed against the inhibition of
HSPs and GRPs, which have been shown to act as powerful anti-
tumour agents both alone and in combination with conventional
therapies.
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